Syncell Inc.  

Taipei, 
Taiwan
http://syncell.com

• Booth: 549

Syncell is a life science technology company building products for next-generation spatial biology. Its pioneering Microscoop™ technology enables microscopy-guided nanoscale protein "scooping", making unbiased subcellular spatial biomarker discovery feasible for the first time. This spatial proteomics technology is applicable to a broad scope of biological problems to help understand molecular mechanisms, identify novel disease biomarkers, and reveal novel druggable targets. It has been used to enable the discovery of novel protein constituents in beta amyloids associated with Alzheimer's disease, TDP-43 aggregates associated with ALS disease, a marker of triple negative breast cancer, etc.

 Press Releases

• New York Structural Biology Center and Syncell Announce Partnership for Microscopy-Guided Proteomics (Oct 30, 2023)

  NEW YORK & TAIPEI, Taiwan--(BUSINESS WIRE)--The New York Structural Biology Center (NYSBC), a global leading institute in structural biology, and Syncell, a life science tools company pioneering the technology of microscopy-guided proteomics discovery, are pleased to announce a partnership to create the Optoproteomics Center of Excellence, part of the new NYSBC Proteomics Core that includes Syncell’s Microscoop platform. This novel spatial proteomic system captures proteins from a specific subcellular structure in cells or tissue biospecimens.

  The Optoproteomics Center of Excellence partnership between the NYSBC and Syncell will advance structural biology toward the protein complex level through the identification of neighboring proteins of a target of interest with Syncell’s technology. The new NYSBC Proteomics Core will expand NYSBC’s existing world-class strengths and gain insights into protein–protein interactions in detail. “It is exciting to create a unique bridge between structural biology and proteomics at the NYSBC,” says Alex de Marco, Director of the Simons Electron Microscopy Center at the NYSBC. “We are thrilled to partner with Syncell and form the Optoproteomics Center of Excellence to expedite this bridging.”

  Accordingly, Syncell will provide a Microscoop platform for NYSBC users to use and perform location-specific protein isolation from a large number of fields of view. The mass spectrometry facility of the NYSBC Proteomics Core will then be implemented to determine the proteome of the isolated proteins, enabling spatial proteomic discovery in high precision. The identified proteome will allow researchers to hypothesize and test which protein–protein interactions might be present. The structural biology of protein complexes can then be further explored with NYSBC’s excellent NMR and cryoEM instrumentation and outstanding technical capacity in structural biology.

  “It is exciting to introduce Syncell’s first global Center of Excellence at the NYSBC,” says Jung-Chi Liao, Founder and CEO of Syncell. “The partnership with the NYSBC Proteomics Core will provide the community unique capability to reveal novel protein constituents within the spatial context.” de Marco adds: “It is expected that many researchers will be benefited by using this new platform to find protein players at their specific regions of interest under a microscope, essential for understanding the role of protein–protein interactions in normal health and disease.”

  “We welcome researchers in the New York area and beyond to try the Microscoop platform for spatial proteomic discovery,” says Liao. “We are hoping that more people can benefit from the discoveries made possible by our technology.”

  The technologies available at the NYSBC are among the best in the world for structural biology research. This collaboration between the NYSBC and Syncell is ideal for maximizing the capabilities of the global community of researchers tasked with advancing scientific discovery, health, and medical care.

• Syncell Appoints Life Science Industry Leaders Dr. Martin Madaus and Dr. Don Kania as Business Strategic Advisors (Oct 30, 2023)

  TAIPEI, Taiwan & LOS ALTOS, Calif.--(BUSINESS WIRE)--Syncell, a life science technology company developing tools for next-generation proteome research, proudly announces the appointment of Dr. Martin Madaus and Dr. Don Kania as the new Business Strategic Advisors of the company. With their extensive backgrounds in the life science industry, both Dr. Madaus and Dr. Kania will guide Syncell's growth and innovation, helping the company become a major player in the spatial proteomics industry.

  Dr. Madaus brings over 30 years of experience in the biotechnology, diagnostics, and pharmaceutical sectors. He is a transformative leader guiding the growth of many companies, currently serving as Chairman of Quanterix, Senior Healthcare Operating Executive of the Carlyle Group, and a Board Member of multiple high-profile biotech companies. His distinguished career includes serving as President, Chairman, and CEO of Millipore, President and CEO of Roche Diagnostics North America, and Chairman and CEO of Ortho-Clinical Diagnostics.

  Dr. Madaus shared enthusiasm about his new role: “Syncell is pushing the boundaries of spatial proteomics with its innovative Microscoop technology. This platform improves our ability to study the functions and interactions of proteins, which is key to understanding the underlying mechanisms of diseases and identifying new drug targets. I am excited to join Syncell as a Business Strategic Advisor and contribute to their mission to advance the field of proteomics with this novel platform."

  Dr. Kania is also a seasoned leader in the field, bringing over 25 years of experience in the life science technology, biotechnology, and photonics industries. He is Chairman of Gandeeva Therapeutics and a Board Member of Intuitive Surgical, Lumicks, and several other startup companies. He is best recognized for his role as CEO and President of FEI Company, which he built to become a global leader in cryo-electron microscopy, a game-changing structural biology technology.

  Dr. Kania commented: “Syncell’s Microscoop technology will contribute to a new era of biological discoveries that could accelerate the development of potentially life-saving drugs. I am honored to be a part of the Syncell team and look forward to helping guide the company's expansion, enabling more researchers access to this groundbreaking tool.”

  Syncell founder and CEO, Jung-Chi Liao, expressed excitement about the appointment of the new Business Strategic Advisors, stating, "We are thrilled to welcome Dr. Martin Madaus and Dr. Don Kania to the Syncell family. Their vast experience and precision leadership in the life science technology sector will undoubtedly elevate our company to new heights, and we look forward to their invaluable contributions."

  As strategic business advisors, Dr. Madaus and Dr. Kania will provide guidance and collaborate with Syncell on various aspects of its operations, including business strategy, commercialization planning, product development, and fundraising efforts.

 Products